SCHEMBL34461111

SCHEMBL34461111

CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DPP3 Q9NY33 5/20 0.56
▸ CXCR4 P61073 2/20 0.54
▸ IL23R Q5VWK5 1/20 0.52
▸ CTSL P07711 3/20 0.52
▸ CTSS P25774 3/20 0.52
▸ CTSK P43235 3/20 0.52
▸ CTSH P09668 1/20 0.52
▸ C5AR1 P21730 1/20 0.51
▸ KISS1R Q969F8 4/20 0.51
▸ CAPN1 P07384 2/20 0.51
▸ CTSB P07858 2/20 0.51
▸ NTSR2 O95665 1/20 0.50
▸ NTSR1 P30989 1/20 0.50
▸ SORT1 Q99523 1/20 0.50
▸ F13A1 P00488 1/20 0.50
▸ TGM2 P21980 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34461090 0.98 DPP3 (0.59) DPP3CXCR4IL23RCTSLCTSS
SCHEMBL34461110 0.95 DPP3 (0.53) DPP3CXCR4IL23RCTSLCTSS
SCHEMBL34461092 0.93 CXCR4 (0.59) DPP3CXCR4C5AR1KISS1RCAPN1
SCHEMBL34461114 0.93 DPP3 (0.55) DPP3CXCR4IL23RCTSLCTSS
SCHEMBL31001650 0.92 CXCR4 (0.61) DPP3CXCR4IL23RC5AR1NTSR2
SCHEMBL34461093 0.91 KISS1R (0.57) DPP3CXCR4IL23RC5AR1KISS1R
SCHEMBL34461097 0.90 CXCR4 (0.59) DPP3CXCR4IL23RC5AR1KISS1R
SCHEMBL31001651 0.89 CXCR4 (0.59) DPP3CXCR4IL23RCTSLCTSS
SCHEMBL5405522 0.88 C5AR1 (0.62) DPP3CXCR4CTSLCTSSCTSK
SCHEMBL5405514 0.88 C5AR1 (0.62) DPP3CXCR4CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R DPP3 359/4885CXCR4 2538/4885IL23R 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback